2 weeks Ago By ABMN Staff
Russell Investments Group Ltd. reduced its stake in Kymera Therapeutics, Inc. ( NASDAQ:KYMR – Free Report ) by 1.
4% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 58,923 shares of the company’s stock after selling 860 shares during the period.
Russell Investments Group Ltd.’s holdings in Kymera Therapeutics were worth $2,370,000 at the end of the most recent quarter. Other large investors have also bought and sold shares of the company.
Blue Trust Inc. lifted its stake in shares of Kymera Therapeutics by 74.8% in the 4th quarter.
Blue Trust Inc. now owns 631 shares of the company’s stock valued at $25,000 after purchasing an additional 270 shares during the period. Harbor Capital Advisors Inc.
grew its position in shares of Kymera Therapeutics by 1.7% in the 4th quarter. Harbor Capital Advisors Inc.
now owns 40,987 shares of the company’s stock worth $1,649,000 after buying an additional 684 shares during the period. KBC Group NV lifted its position in Kymera Therapeutics by 53.8% during the 4th quarter.
KBC Group NV now owns 2,151 shares of the company’s stock valued at $87,000 after acquiring an additional 752 shares during the period. China Universal Asset Management Co. Ltd.
boosted its stake in Kymera Therapeutics by 10.6% during the fourth quarter. China Universal Asset Management Co.
Ltd. now owns 13,733 shares of the company’s stock worth $552,000 after acquiring an additional 1,311 shares in the last quarter. Finally, Arizona State Retirement System lifted its holdings in shares of Kymera Therapeutics by 15.
5% during the fourth quarter. Arizona State Retirement System now owns 11,221 shares of the company’s stock valued at $451,000 after purchasing an additional 1,503 shares during the last quarter. Wall Street Analysts Forecast Growth A number of research firms recently weighed in on KYMR.
HC Wainwright raised their price objective on Kymera Therapeutics from $54.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, February 28th.
Citigroup started coverage on shares of Kymera Therapeutics in a research note on Thursday, March 13th. They issued a “buy” rating and a $52.00 price target on the stock.
Leerink Partners reaffirmed an “outperform” rating and issued a $60.00 target price on shares of Kymera Therapeutics in a report on Friday, December 27th. Finally, Stephens reiterated an “overweight” rating and set a $60.
00 price target on shares of Kymera Therapeutics in a report on Tuesday, January 21st. Three equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.
com, the stock currently has an average rating of “Moderate Buy” and an average price target of $56.36. Kymera Therapeutics Trading Up 3.
8 % Shares of NASDAQ KYMR opened at $25.97 on Friday. Kymera Therapeutics, Inc.
has a 12-month low of $19.45 and a 12-month high of $53.27.
The firm has a market capitalization of $1.69 billion, a price-to-earnings ratio of -11.10 and a beta of 2.
22. The firm has a 50 day moving average of $30.47 and a 200 day moving average of $39.
04. Kymera Therapeutics ( NASDAQ:KYMR – Get Free Report ) last released its earnings results on Thursday, February 27th. The company reported ($0.
88) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.12).
The company had revenue of $7.39 million for the quarter, compared to analysts’ expectations of $14.81 million.
Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%.
Sell-side analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.
Insiders Place Their Bets In other news, COO Jeremy G. Chadwick sold 1,383 shares of the company’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.
45, for a total value of $42,112.35. Following the completion of the transaction, the chief operating officer now owns 67,800 shares of the company’s stock, valued at $2,064,510.
This represents a 2.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink .
Also, CFO Bruce N. Jacobs sold 7,035 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.
45, for a total value of $214,215.75. Following the sale, the chief financial officer now directly owns 201,886 shares in the company, valued at $6,147,428.
70. This trade represents a 3.37 % decrease in their position.
The disclosure for this sale can be found here . In the last 90 days, insiders have sold 10,659 shares of company stock worth $324,567. Company insiders own 15.
82% of the company’s stock. About Kymera Therapeutics ( Free Report ) Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
Further Reading Want to see what other hedge funds are holding KYMR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kymera Therapeutics, Inc. ( NASDAQ:KYMR – Free Report ).
Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
